JP2019524772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524772A5 JP2019524772A5 JP2019505229A JP2019505229A JP2019524772A5 JP 2019524772 A5 JP2019524772 A5 JP 2019524772A5 JP 2019505229 A JP2019505229 A JP 2019505229A JP 2019505229 A JP2019505229 A JP 2019505229A JP 2019524772 A5 JP2019524772 A5 JP 2019524772A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treating
- disease
- liver
- hyperlipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 12
- 208000028867 ischemia Diseases 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 230000004064 dysfunction Effects 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 206010040882 skin lesion Diseases 0.000 claims description 8
- -1 cyclic oligosaccharide Chemical class 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 208000001395 Acute radiation syndrome Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 206010067125 Liver injury Diseases 0.000 claims description 4
- 150000002009 diols Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000006372 lipid accumulation Effects 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 231100000234 hepatic damage Toxicity 0.000 claims description 3
- 230000008818 liver damage Effects 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000005976 liver dysfunction Effects 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims 4
- 230000037356 lipid metabolism Effects 0.000 claims 2
- 230000013190 lipid storage Effects 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 231100000444 skin lesion Toxicity 0.000 claims 2
- DTGDZMYNKLTSKC-HKQCOZBKSA-N cholest-5-ene Chemical compound C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 DTGDZMYNKLTSKC-HKQCOZBKSA-N 0.000 claims 1
- DTGDZMYNKLTSKC-UHFFFAOYSA-N cholest-5-ene Natural products C1C=C2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 DTGDZMYNKLTSKC-UHFFFAOYSA-N 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000030833 cell death Effects 0.000 description 3
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122494A JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2024075682A JP2024105442A (ja) | 2016-08-02 | 2024-05-08 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370024P | 2016-08-02 | 2016-08-02 | |
| US62/370,024 | 2016-08-02 | ||
| US201762470578P | 2017-03-13 | 2017-03-13 | |
| US62/470,578 | 2017-03-13 | ||
| PCT/US2017/044840 WO2018026781A1 (en) | 2016-08-02 | 2017-08-01 | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122494A Division JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524772A JP2019524772A (ja) | 2019-09-05 |
| JP2019524772A5 true JP2019524772A5 (enExample) | 2020-08-20 |
Family
ID=61073854
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505229A Pending JP2019524772A (ja) | 2016-08-02 | 2017-08-01 | ５−コレステン−３，２５−ジオール，３−サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2022122494A Active JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2024075682A Pending JP2024105442A (ja) | 2016-08-02 | 2024-05-08 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122494A Active JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2024075682A Pending JP2024105442A (ja) | 2016-08-02 | 2024-05-08 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20190269695A1 (enExample) |
| EP (2) | EP4101861A1 (enExample) |
| JP (3) | JP2019524772A (enExample) |
| KR (3) | KR20230152787A (enExample) |
| CN (2) | CN109983025B (enExample) |
| AU (2) | AU2017305239C1 (enExample) |
| CA (1) | CA3031224A1 (enExample) |
| CY (1) | CY1125567T1 (enExample) |
| DK (1) | DK3494125T3 (enExample) |
| EA (1) | EA201990438A1 (enExample) |
| ES (1) | ES2922933T3 (enExample) |
| HR (1) | HRP20220932T1 (enExample) |
| HU (1) | HUE059768T2 (enExample) |
| IL (2) | IL298681A (enExample) |
| LT (1) | LT3494125T (enExample) |
| MX (2) | MX2019001323A (enExample) |
| PL (1) | PL3494125T3 (enExample) |
| PT (1) | PT3494125T (enExample) |
| RS (1) | RS63529B1 (enExample) |
| SI (1) | SI3494125T1 (enExample) |
| SM (1) | SMT202200330T1 (enExample) |
| TW (1) | TWI815796B (enExample) |
| WO (1) | WO2018026781A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| AU2014369916A1 (en) | 2013-12-24 | 2016-06-16 | Durect Corporation | Uses of oxygenated cholesterol sulfates (OCS) |
| PT3494125T (pt) | 2016-08-02 | 2022-07-07 | Durect Corp | Composições compreendendo 5-colesten-3, 25-diol, 3-sulfato (25hc3s), ou seu sal farmaceuticamente aceitável, e, pelo menos, um oligossacárido cíclico |
| EP4037650A4 (en) * | 2019-09-30 | 2023-10-18 | Durect Corporation | Treatment of alcoholic hepatitis |
| IL294286A (en) * | 2019-12-27 | 2022-08-01 | Durect Corp | Crystalline and liquid crystalline sodium 25-hydroxycholine-5-yne-5-sulfate and methods for its preparation |
| AU2021221109A1 (en) * | 2020-02-11 | 2022-08-25 | Durect Corporation | Treatment of infectious diseases |
| WO2021202608A1 (en) * | 2020-03-31 | 2021-10-07 | The Regents Of The University Of Michigan | Serum metabolites as biomarkers for carnitine treatment of sepsis |
| AU2021273936A1 (en) * | 2020-05-22 | 2022-12-08 | Durect Corporation | Treatment of non-alcoholic steatohepatitis (NASH) |
| JP2023531735A (ja) * | 2020-06-26 | 2023-07-25 | デュレクト コーポレーション | インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用 |
| CN112967234B (zh) * | 2021-02-09 | 2022-12-09 | 复旦大学附属中山医院 | 冠状动脉功能生理学病变模式定量评价方法 |
| WO2022272103A1 (en) * | 2021-06-25 | 2022-12-29 | Durect Corporation | 25-hydroxy-cholest-5-en-3-sulfate choline and methods for preparing, and uses of, same |
| CN113750039B (zh) * | 2021-10-26 | 2023-08-18 | 浙江中医药大学 | 一种黄芩苷-海藻酸钙温敏纳米凝胶、制备方法及其应用 |
| WO2023196412A1 (en) * | 2022-04-06 | 2023-10-12 | Nobias Therapeutics, Inc. | Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same |
| CN119896674A (zh) * | 2023-10-27 | 2025-04-29 | 上海交通大学医学院附属新华医院 | 胆固醇硫酸酯在制备治疗特应性皮炎的药物中的应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| BE794362A (fr) | 1972-01-22 | 1973-07-23 | Merck Patent Gmbh | Sulfates hydrosolubles de sterine |
| US3928397A (en) | 1973-03-02 | 1975-12-23 | Eisai Co Ltd | New 5-cholestene derivatives and preparation thereof |
| US3822254A (en) | 1973-05-21 | 1974-07-02 | Hoffmann La Roche | Synthesis of 25-hydroxycholesterol |
| US4264512A (en) | 1975-09-29 | 1981-04-28 | The Regents Of The University Of California | 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof |
| US4202891A (en) | 1977-05-16 | 1980-05-13 | Kandutsch Andrew A | 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols |
| GB1595020A (en) | 1977-06-24 | 1981-08-05 | Chugai Pharmaceutical Co Ltd | 3a-hydroxy steroid derivatives of the cholestane series |
| US4427668A (en) | 1982-04-01 | 1984-01-24 | New York University | 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US5510340A (en) | 1992-06-12 | 1996-04-23 | Sri International | Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use |
| US5371077A (en) | 1992-08-03 | 1994-12-06 | William Marsh Rice University | Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them |
| US5599659A (en) | 1993-03-11 | 1997-02-04 | Breonics, Inc. | Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate |
| US5587368A (en) * | 1993-11-30 | 1996-12-24 | New York University | Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury |
| PL185622B1 (pl) | 1995-06-23 | 2003-06-30 | Novo Nordisk As | Zastosowanie związku steroidowego i sposób regulacji mejozy w komórce rozrodczej ssaka |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| US7012069B2 (en) | 2001-05-03 | 2006-03-14 | Arch Development Corporation | Liver X receptor agonists |
| DE69913513T2 (de) | 1998-05-13 | 2004-09-30 | Novo Nordisk A/S | Verwendung von verbindungen mit der fähigkeit die meiose zu regulieren |
| IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| BR0010197A (pt) | 1999-04-30 | 2002-07-16 | Arch Dev Corp | Derivados de esteróides |
| US20060025393A1 (en) | 1999-04-30 | 2006-02-02 | Shutsung Liao | Steroid derivatives |
| WO2001015676A2 (en) | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| JP4018312B2 (ja) | 2000-02-21 | 2007-12-05 | 株式会社ルネサステクノロジ | 無線通信装置 |
| IN191090B (enExample) | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
| EP1385868A4 (en) | 2001-02-08 | 2004-12-08 | Univ Chicago | STEROID DERIVATIVE |
| US20020164310A1 (en) | 2001-03-02 | 2002-11-07 | Mgvs Ltd. | Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| CA2466033A1 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| DE60327225D1 (de) * | 2002-08-20 | 2009-05-28 | Bristol Myers Squibb Co | Aripiprazol-komplex-formulierung und verfahren |
| WO2006003150A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| CA2637884A1 (en) | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| DE102006021181B3 (de) | 2006-05-06 | 2007-05-03 | Laux, Thomas, Dr. | Zahnprothesen-Trägerimplantat |
| GB0625965D0 (en) | 2006-12-23 | 2007-02-07 | Renovo Ltd | Medicaments for wound healing |
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| US8831674B2 (en) | 2007-09-27 | 2014-09-09 | Multi-Tech Systems, Inc. | Message server |
| RU2460525C2 (ru) | 2008-01-04 | 2012-09-10 | Эл Джи Лайф Сайенсиз Лтд. | Производные индола и индазола, обладающие консервирующим действием по отношению к клеткам, тканям и органам |
| WO2011077245A2 (en) | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| WO2012017290A1 (en) * | 2010-08-04 | 2012-02-09 | Carlo Ghisalberti | Inclusion complexes of cyclodextrins with spermidine, and proliferative/reparative compositions comprising thereof |
| KR101739816B1 (ko) * | 2010-12-01 | 2017-05-25 | 주식회사유한양행 | 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말 |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| FI2753632T3 (fi) | 2011-09-08 | 2023-08-02 | Sage Therapeutics Inc | Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä |
| JP6125610B2 (ja) * | 2012-04-12 | 2017-05-10 | ヴァージニア コモンウェルス ユニバーシティ | 代謝障害、高脂血症、糖尿病、脂肪性肝疾患及びアテローム性動脈硬化症の治療のための新規コレステロール代謝物、５−コレステン−３β，２５−ジオールジスルファート（２５ＨＣＤＳ） |
| WO2014015024A2 (en) | 2012-07-17 | 2014-01-23 | Regents Of The University Of Michigan | Non-surgical method of treatment for cataract |
| CN107865968B (zh) | 2012-08-03 | 2021-03-05 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗溶酶体贮积症的环糊精 |
| WO2014121235A2 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| EP2842547A1 (en) * | 2013-08-27 | 2015-03-04 | Freund Pharmatec Ltd. | Improved fenofibrate compositions |
| AU2014369916A1 (en) | 2013-12-24 | 2016-06-16 | Durect Corporation | Uses of oxygenated cholesterol sulfates (OCS) |
| EP3204011A4 (en) * | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| MX376196B (es) | 2014-10-10 | 2025-03-07 | Univ Virginia Commonwealth | Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno del almacenamiento lipidico. |
| EP3328389A1 (en) | 2015-07-27 | 2018-06-06 | Catacore, Inc. | Compositions for the treatment of cataracts |
| PT3494125T (pt) | 2016-08-02 | 2022-07-07 | Durect Corp | Composições compreendendo 5-colesten-3, 25-diol, 3-sulfato (25hc3s), ou seu sal farmaceuticamente aceitável, e, pelo menos, um oligossacárido cíclico |
| BR112019001193A2 (pt) | 2016-08-02 | 2019-04-30 | Virginia Commonwealth University | uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele |
| BR112019001225A2 (pt) | 2016-08-02 | 2019-04-30 | Durect Corporation | composições compreendendo sulfato de colesterol oxigenado e pelo menos um dentre polialquileno glicol, carboximetil celulose e polioxilglicerídeo |
| EP4037650A4 (en) | 2019-09-30 | 2023-10-18 | Durect Corporation | Treatment of alcoholic hepatitis |
| IL294286A (en) | 2019-12-27 | 2022-08-01 | Durect Corp | Crystalline and liquid crystalline sodium 25-hydroxycholine-5-yne-5-sulfate and methods for its preparation |
| AU2021221109A1 (en) | 2020-02-11 | 2022-08-25 | Durect Corporation | Treatment of infectious diseases |
| AU2021273936A1 (en) | 2020-05-22 | 2022-12-08 | Durect Corporation | Treatment of non-alcoholic steatohepatitis (NASH) |
| US20230181602A1 (en) | 2020-05-22 | 2023-06-15 | Durect Corporation | Treatment of non-alcoholic steatohepatitis (nash) |
| JP2023531735A (ja) | 2020-06-26 | 2023-07-25 | デュレクト コーポレーション | インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用 |
-
2017
- 2017-08-01 PT PT178375168T patent/PT3494125T/pt unknown
- 2017-08-01 LT LTEPPCT/US2017/044840T patent/LT3494125T/lt unknown
- 2017-08-01 HR HRP20220932TT patent/HRP20220932T1/hr unknown
- 2017-08-01 KR KR1020237036153A patent/KR20230152787A/ko not_active Ceased
- 2017-08-01 ES ES17837516T patent/ES2922933T3/es active Active
- 2017-08-01 AU AU2017305239A patent/AU2017305239C1/en active Active
- 2017-08-01 SM SM20220330T patent/SMT202200330T1/it unknown
- 2017-08-01 EA EA201990438A patent/EA201990438A1/ru unknown
- 2017-08-01 EP EP22173674.7A patent/EP4101861A1/en active Pending
- 2017-08-01 IL IL298681A patent/IL298681A/en unknown
- 2017-08-01 EP EP17837516.8A patent/EP3494125B1/en active Active
- 2017-08-01 PL PL17837516.8T patent/PL3494125T3/pl unknown
- 2017-08-01 MX MX2019001323A patent/MX2019001323A/es unknown
- 2017-08-01 US US16/320,079 patent/US20190269695A1/en not_active Abandoned
- 2017-08-01 RS RS20220815A patent/RS63529B1/sr unknown
- 2017-08-01 SI SI201731214T patent/SI3494125T1/sl unknown
- 2017-08-01 TW TW106125936A patent/TWI815796B/zh active
- 2017-08-01 KR KR1020227038844A patent/KR102593667B1/ko active Active
- 2017-08-01 CA CA3031224A patent/CA3031224A1/en active Pending
- 2017-08-01 CN CN201780055805.8A patent/CN109983025B/zh active Active
- 2017-08-01 DK DK17837516.8T patent/DK3494125T3/da active
- 2017-08-01 CN CN202310244445.3A patent/CN116747233A/zh active Pending
- 2017-08-01 KR KR1020197005371A patent/KR102465046B1/ko active Active
- 2017-08-01 WO PCT/US2017/044840 patent/WO2018026781A1/en not_active Ceased
- 2017-08-01 JP JP2019505229A patent/JP2019524772A/ja active Pending
- 2017-08-01 HU HUE17837516A patent/HUE059768T2/hu unknown
-
2019
- 2019-01-22 IL IL264390A patent/IL264390B2/en unknown
- 2019-01-30 MX MX2022013429A patent/MX2022013429A/es unknown
-
2020
- 2020-11-10 US US17/094,432 patent/US11406646B2/en active Active
-
2022
- 2022-06-16 AU AU2022204217A patent/AU2022204217B2/en active Active
- 2022-06-28 US US17/852,142 patent/US12226423B2/en active Active
- 2022-08-01 JP JP2022122494A patent/JP7487264B2/ja active Active
- 2022-09-20 CY CY20221100625T patent/CY1125567T1/el unknown
-
2024
- 2024-05-08 JP JP2024075682A patent/JP2024105442A/ja active Pending
-
2025
- 2025-01-06 US US19/011,381 patent/US20250249021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220932T1 (hr) | Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid | |
| US9333190B2 (en) | Endoxifen compositions and methods | |
| US12318364B2 (en) | Isoflavonoid compositions and methods for the treatment of cancer | |
| JP2018537437A5 (enExample) | ||
| US20110137057A1 (en) | Unsaturated Steroid Compounds | |
| RU2013152751A (ru) | Лиофилизированный препарат цитотоксических дипептидов | |
| CN101242820A (zh) | 双（硫酰肼酰胺）调配物 | |
| JP6734971B2 (ja) | がん治療薬 | |
| US20130109700A1 (en) | Topical Itraconazole Formulations and Uses Thereof | |
| ES2661106T3 (es) | Formulaciones de crema estabilizadas que comprenden aceite de sándalo | |
| US20220249540A1 (en) | Inhalable composition compromising cyclodextrin for use in the treatment of nasal inflammations | |
| JP2019501191A5 (enExample) | ||
| JP5788982B2 (ja) | ベンダムスチンアニオン性−カチオン性シクロポリサッカライド組成物 | |
| Shang et al. | MSCs ameliorate hepatic IR injury by modulating phenotypic transformation of kupffer cells through drp-1 dependent mitochondrial dynamics | |
| CN107281165A (zh) | 一种雷公藤甲素‑叶酸靶向纳米药物及其制备方法和应用 | |
| HRP20201300T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
| JP7597778B2 (ja) | シクロデキストリン及びブスルファンを含有する組成物 | |
| EP4288053A1 (en) | Small molecule inhibitors of cd38 as immunosuppressants | |
| EP3888637A1 (en) | Lyophilized preparation for prostaglandin e1 methyl ester injection, preparation thereof and application thereof | |
| CN102526038A (zh) | 替莫唑胺的脑靶向药物组合物及其应用 | |
| CN102552140B (zh) | 罗格列酮的液体组合物 | |
| CN102040643B (zh) | 环索奈德硝酸酯衍生物 | |
| CN102949725A (zh) | 一种含有糖皮质激素和nos抑制剂的注射药物组合物 | |
| CN104857014A (zh) | 2-羟丙基-β-环化糊精在制备治疗X-连锁肾上腺脑白质退化症的药物中的应用 | |
| AU2021374726A9 (en) | Compositions comprising methyl cyclodextrins for the treatment and/or prevention of hepatic steatosis |